Lucrative market opportunity in nonalcoholic steatohepatitis; Report

The lack of a simple diagnostic test and low physician awareness coupled with the lack of therapeutics are all contributing to under-diagnosis of nonalcoholic steatohepatitis (NASH), a new research reveals.

Decision Resources Group’s study estimates the prevalence of NASH to be four to ten percent in major markets under study, including the USA, Germany, France, Spain, Italy and UK, fueled in large part by the current obesity epidemic.

Tremendous unmet need exists for NASH therapies in developed markets, particularly among patients with advanced liver disease, driven in part by a large patient population that is further anticipated to grow due to aging. Currently, a hefty pharmaceutical pipeline of NASH therapeutics is progressing through clinical trials. However, our research reveals that only patients with advanced liver disease are likely to be treated with emerging agents.